Loading...
XASXPAA
Market cap55mUSD
Nov 11, Last price  
0.19AUD
Name

Pharmaust Ltd

Chart & Performance

D1W1MN
XASX:PAA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.07%
Rev. gr., 5y
-0.33%
Revenues
0k
-100.00%
3,210,8666,105,7547,131,0002,794,5811,755,6221,640,8381,552,4771,617,8141,710,2551,939,3902,371,3262,717,9133,307,5773,259,0014,346,7563,195,8922,140,3203,381,2732,823,9060
Net income
-9m
L+45.41%
-3,363,712-2,752,284-6,575,000-5,767,973-179,596-438,600-5,797,886-4,260,420-514,883-1,317,853-1,925,091-3,927,256-1,343,614-2,521,679-1,551,222-1,361,990-1,337,310-1,708,209-6,211,560-9,032,356
CFO
-5m
L+230.43%
00000000-305,460-1,588,355-1,751,246-1,599,878-1,255,666-1,550,797-1,554,006-1,270,002-937,965-1,332,263-1,564,178-5,168,567
Earnings
Feb 26, 2025

Profile

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.
URL
https://www.pharmaust.com/
IPO date
Oct 05, 2001
Employees
52
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
2,824
-16.48%
3,381
57.98%
Cost of revenue
3,848
6,447
6,130
Unusual Expense (Income)
NOPBT
(3,848)
(3,623)
(2,749)
NOPBT Margin
Operating Taxes
(553)
1
3
Tax Rate
NOPAT
(3,295)
(3,623)
(2,749)
Net income
(9,032)
45.41%
(6,212)
263.63%
(1,708)
27.73%
Dividends
Dividend yield
Proceeds from repurchase of equity
13,307
2,244
718
BB yield
-18.40%
-9.32%
-3.24%
Debt
Debt current
158
348
Long-term debt
1,781
2,074
Deferred revenue
Other long-term liabilities
3
31
Net debt
(9,718)
(771)
2
Cash flow
Cash from operating activities
(5,169)
(1,564)
(1,332)
CAPEX
(3)
(35)
(43)
Cash from investing activities
(1,165)
(35)
(43)
Cash from financing activities
13,342
1,889
771
FCF
(3,804)
107
(2,458)
Balance
Cash
9,718
2,710
2,420
Long term investments
Excess cash
9,718
2,569
2,251
Stockholders' equity
10,228
3,889
7,844
Invested Capital
511
2,372
7,010
ROIC
ROCE
EV
Common stock shares outstanding
370,811
321,009
316,885
Price
0.20
160.00%
0.08
7.14%
0.07
-23.08%
Market cap
72,308
200.34%
24,076
8.54%
22,182
-22.80%
EV
62,590
23,305
22,184
EBITDA
(3,847)
(3,296)
(2,434)
EV/EBITDA
Interest
82
89
Interest/NOPBT